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CC BY-NC-ND license (http://creativeAbstract Human Epidermal Growth Factor Receptor type 2 (HER2) gene amplification and/or
protein overexpression is observed in patients suffering from HER2þ breast cancer. This sub-
type of breast cancer has improved prognosis due to availability of anti-HER2 therapy. Howev-
er, drug resistance and tumor recurrence still remains a major concern. Cancer Stem Cells
(CSCs) are believed to constitute the subset of cell population that is resistant to drug treat-
ment and possesses characteristics of stem cells. CSCs enable the tumors to thrive despite ma-
jor insults. This review provides a comprehensive idea about the concept of CSCs in context of
HER2þ breast cancer by providing the description of the markers that are used for the identi-
fication of CSCs and by elucidating the signaling pathways that are associated with HER2þ
breast CSCs. Furthermore, the review also describes the interaction of HER2 with those
signaling pathways and the future of targeting CSCs in HER2þ breast cancer.
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an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Breast cancer is the most common cancer among women
worldwide. It remains the second leading cause of cancer-
related death among women in the United States, and
about one in eight U.S. women would be diagnosed witht Ave, Maywood, IL 60153, USA. T
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commons.org/licenses/by-nc-nd/breast cancer in her lifetime. In 2016, about 40,450 U.S.
women are expected to die due to breast cancer.1,2 Breast
cancer is a heterogeneous disease and could be categorized
into four major subtypes e Luminal A, Luminal B, HER2 and
triple negative (basal-like). These breast cancer subtypes
are summarized in the table below (Table 1).3,4el.: þ1 708 327 2372.
and hosting by Elsevier B.V. This is an open access article under the
4.0/).
Table 1 Subtypes of breast cancer.
Molecular
subtype
Prevalence Characteristics Treatment
response
Luminal
A
40% ERþ and/or PRþ,
HER2þ, low Ki67
Best Prognosis. Respond to endocrine therapy
(tamoxifen, fulvestrant and aromatase inhibitors).
Less response to chemotherapy as compared to Luminal B.
Luminal
B
20% ERþ and/or PRþ,
HER2þ/, high Ki67
Better respond to chemotherapy as
compared to endocrine therapy due to high Ki67.
Poor prognosis as compared to Luminal A
HER2 15e20% ER-, PR- and HER2þ Improved prognosis due to drugs like humanized therapeutic
monoclonal antibodies trastuzumab & pertuzumab, taxane based
chemotherapy, antibody drug conjugate T-DM1 and dual
EGFR/HER2 tyrosine kinase inhibitor lapatinib.
Triple
Negative/Basal like
10e15% ER-, PR-, HER2- Worst prognosis due to lack of targeted therapy.
Combination of surgery, radiation therapy and chemotherapy.
Listed are the major subtypes of breast cancer. Also included are their characteristics, prevalence rate and treatment response.
ERþ: estrogen receptor positive; ER-: estrogen receptor negative.
PRþ: progesterone receptor positive; PR-: progesterone receptor negative.
HER2þ: human epidermal growth factor receptor 2 positive.
HER2-: human epidermal growth factor receptor 2 negative.
EGFR: epidermal growth factor receptor; T-DM1: trastuzumab emtansine.
Table 2 Ligands for HER family receptors.
HER
receptor
Ligands
HER1 Amphiregulin, Epidermal
Growth Factor (EGF), Epigen,
Epiregulin, b-Cellulin, Heparin-Binding
EGF-like Growth Factor (HBEGF) and
Transforming Growth Factor e a
HER3 Neuregulin1 and Neuregulin2
HER4 Neuregulin1, Neureulin2,
Neuregulin3, Neuregulin4,
b-Cellulin, Heparin-Binding
EGF-like Growth Factor (HBEGF)
and Epiregulin
HER2þ breast cancer stem cells 115The current review would primarily focus on HER2þ
subtype of breast cancer.
HER2 signaling pathway
HER2 subtype of breast cancer is associated with gene
amplification and/or protein overexpression of Human
epidermal growth factor receptor 2 (HER2/neu), also
known as ErbB2 which leads to aggressive tumor growth and
poor clinical outcome. HER2 belongs to HER family of re-
ceptor tyrosine kinase. Other members of the family
include HER1 (also known as Epidermal Growth Factor Re-
ceptor or EGFR and ErbB1), HER3 (also known as ErbB3) and
HER4 (also known as ErbB4). HER receptors contain an
extracellular ligand binding domain containing two
cysteine-rich regions, lipophilic alpha helical trans-
membrane domain and an intracellular cytoplasmic
domain.
Specific ligand binds to the HER receptor at the ligand
binding domain, which then leads to homodimerization or
heterodimerization of the HER receptors. The receptor
dimerization is followed by autophosphorylation and trans-
phosphorylation of specific tyrosine residues within the
intracellular tyrosine kinase domain. Depending upon the
ligand involved and the resulting HER dimer formed, spe-
cific tyrosine residues would be autophosphorylated and
would affect the recruitment of adaptor proteins and
downstream activation of signaling pathways. The most
common effectors of HER signaling include mitogen-
activated protein kinase (MAPK) pathway, Phosphoinosi-
tide-3-kinase (PI3K)/Akt signaling pathway and protein ki-
nase C (PKC) activation. The signaling pathways are
involved in cell survival, cell proliferation, adhesion,
migration, differentiation and apoptosis. Biological
response depends on the ligand involved, the dimer formed
as well as on cellular context. The known ligands for HER
receptors are listed in the table below (Table 2). There areno known ligands for HER2 and HER3 lacks intrinsic tyrosine
kinase activity and for the same reason HER2 and HER3 are
preferred dimerization partners.5,6 Signaling through HER
receptors is attenuated by ligand mediated endocytosis of
receptors.HER2 therapy
First line treatment for advanced, HER2þ breast cancer
patients includes combination of therapeutic humanized
monoclonal antibodies pertuzumab and trastuzumab and
taxane-based chemotherapy, unless the patient has severe
heart problems. Along with being HER2þ, if the cancer is
hormone receptor positive, the treatment includes combi-
nation of hormonal therapy and anti-HER2 therapy.
In case of de novo resistance to trastuzumab or if the
tumor recurrence is observed within 12 months,
trastuzumab-emtansine (T-DM1) is used as a second line of
116 D. Shah, C. Osipotreatment. T-DM1 is an antibody drug conjugate consisting
of therapeutic humanized monoclonal antibody trastuzu-
mab linked to cytotoxic agent DM1.
Third line treatment includes dual HER2-EGFR tyrosine
kinase inhibitor lapatinib along with capecitabine or
other combinations of chemotherapy and anti-HER2
therapy.3
Other potential therapeutics
Cyclin dependent kinase inhibitors
Cell cycle dysregulation is one of the most important hall-
marks of cancer. Cyclin dependent kinase 4/6 (CDK 4/6)
inhibitors are currently being investigated extensively. The
CDK 4/6 acts by forming a complex with Cyclin D1 and
phosphorylating retinoblastoma protein (Rb). The phos-
phorylation results in inactivation of Rb and allows cells to
transition from the G1 phase into S phase of the cell cycle.
The inhibitors act by preventing the interaction between
Cyclin D1 and CDK 4/6, and thus blocking the entry from the
G1 phase into S phase. Recently, the FDA approved the use
of CDK 4/6 inhibitor palbociclib in combination with letro-
zole for the treatment of postmenopausal women suffering
from ERþ/HER2-advanced metastatic breast cancer. Other
CDK 4/6 inhibitors that have been developed are abema-
ciclib and LEE01.
In the HER2 setting, palbociclib, either alone, or in
combination with trastuzumab showed growth inhibitory
effects on HER2þ cell lines. Currently, a phase II clinical
trial has been undertaken to assess the safety and efficacy
of palbociclib and trastuzumab, with or without letrozole,
in post-menopausal patients with HER2-positive locally
advanced or metastatic breast cancer (MBC) who have
received prior chemotherapy and trastuzumab for their
metastatic disease.7
Immune checkpoint inhibitors
Tumor antigens are recognized by T lymphocytes, which
mediate an immune response against cancer cells. During
this attack by T and other immune cells, the immune
system enhances the activation of certain molecules
known as checkpoints. Checkpoints prevent the immune
reaction from damaging normal tissues in the body.
Cancer cells are known to upregulate the expression
of immune checkpoint molecules in order to escape the
attack of the immune system. Such checkpoint molecules
include cytotoxic T lymphocyteeassociated protein-4
(CTLA-4) and a co-inhibitory receptor called Pro-
grammed death 1 (PD-1), which is overexpressed on
tumor-infiltrating lymphocytes (TILs). PD-L1 is the ligand
for PD-1 and is overexpressed in various forms of cancer,
including breast cancer. PD-1 expressing TILs are asso-
ciated with poor overall survival in HER2þ breast cancer.
Moreover, a positive correlation is observed between the
expression of PD-L1 and anti PD-1 therapy.
PD-1 inhibitors have shown promising results during the
initial evaluation in triple negative breast cancer.
Furthermore, Anti-PD1 antibodies showed encouraging re-
sults in HER2þ breast cancer during the preclinical studies,as synergistic effects were observed with the combination
of trastuzumab and anti-PD1 antibodies. Currently, a phase
II clinical trial is being undertaken to assess the efficacy of
using anti-PD-1 monoclonal antibody and trastuzumab in
patients with trastuzumab-resistant, HER2-positive meta-
static breast cancers.8
Recent work by Mu¨ller et al demonstrates that T-DM1
promotes the immune system. Despite primary resis-
tance to immunotherapy, the combination of T-DM1 with
anti CTLA-4 and anti PD-1 inhibitors renders HER2þ
breast cancer susceptible to immune attack.9
Combining chemotherapy with immunotherapy would
be an exciting strategy that needs to be thoroughly
investigated.
Drug resistance and cancer stem cell
hypothesis
Despite improved prognosis of the HER2 subtype of breast
cancer due to the availability of targeted agents, drug
resistance and tumor recurrence still remains a major
concern. A fraction of patients are intrinsically resistant to
drug treatment (denovo drug resistance) whereas others
acquire drug resistance over the course of treatment (ac-
quired drug resistance). Reports indicate that breast cancer
recurrence might occur up to 25 years after the treatment
of primary tumor.10
Possible mechanisms for trastuzumab resistance include
e overexpression of other HER family receptors, Insulin-like
growth factor 1 receptor (IGF1R) upregulation, increased
expression and activity of c-Met (mesenchymal-epithelial
transition factor) receptor, overexpression of EphA2 re-
ceptor, overexpression of PDK1, increased activation of
PI3K signaling pathway, increased Src activity, loss of tumor
suppressor phosphatase and tensin homolog (PTEN), loss of
p27kip1, increased expression of membrane associated
glycoprotein MUC4, HER2 mutation(s) that alters the bind-
ing of trastuzumab to HER2, expression of amino-terminus
truncated form of HER2-p95HER2 which sterically hinders
the binding of HER2 and trastuzumab, expression of a splice
variant that removes exon 16 in the extracellular domain of
HER2 and rare incidence of antibody development against
trastuzumab. Moreover, the inability of the host immune
system to exhibit an antibody-dependent cell-mediated
cytotoxicity (ADCC) response could contribute to de novo
resistance.11e13
Lapatinib resistance may be mediated by the following
I Activation of compensatory pathways: These include
signaling through other HER family receptor tyrosine
kinases as well as through c-Met and AXL, altered
signaling through PI3 Kinase/Akt/mTOR and Src family of
non-receptor tyrosine kinase, overexpression of Protein
Tyrosine Kinase 6 (PTK6), activation of multiple tyrosine
kinases, increased levels of receptor tyrosine kinase li-
gands and activation of estrogen receptor (ER) pathway.
II Mutations in HER2 tyrosine kinase domain e Various
HER2 amino acid substitutions have been identified to be
involved in mediating lapatinib resistance. The HER2
L755S and T798I and EGFR T790M were associated with
high level of lapatinib resistance.
HER2þ breast cancer stem cells 117III Gene Amplification e Various genes that are amplified
and overexpressed in HER2þ breast cancer can lead to
lapatinib resistance. One such gene implicated in
mediating resistance is NIBP (TRAPPC9, trafficking pro-
tein particle complex 9).14
The cancer stem cell hypothesis states that tumors
contain a subpopulation of cells that possess the properties
of stem cells and are called cancer stem cells (CSCs) or
tumor initiating cells (TICs). These cells drive the growth of
the tumor and are responsible for resistance to radiation
and chemotherapy and tumor recurrence. CSCs are at the
apex of the hierarchy and can lead to formation of other
tumorigenic CSCs through self-renewal and can form the
non-tumorigenic bulk by differentiation.15
There is controversy in the literature regarding the term
“Cancer Stem Cells”. CSCs may or may not arise from
normal stem cells. However, they do fulfill the criteria of a
true stem cell through their ability of self-renewal and
capability to recapitulate all the cell types in a given tissue.
Hence, for the purpose of this review, the term CSCs would
be used hereafter.16
Epithelial to Mesenchymal Transition (EMT) is a phe-
nomenon by which the cells lose their epithelial char-
acteristics and acquire mesenchymal traits. It is
characterized by the loss of epithelial markers like E-
cadherin and cytokeratin and enhancement of mesen-
chymal markers like N-cadherin, fibronectin and vimen-
tin. EMT as well as its reverse process Mesenchymal to
Epithelial Transition (MET) are critical processes during
embryonic development. The pioneering work done by
Robert Weinberg’s group (Mani et al) demonstrates that
induction of EMT in non-tumorigenic immortalized
human mammary epithelial cells using ectopic over-
expression of EMT transcription factors such as Snail or
Twist results in fibroblast like mesenchymal looking cells
displaying traits of CSCs as assessed by mammosphere
formation and through levels of CD44 high and CD24 low.
The markers used for the assessment of CSCs are dis-
cussed in the later part of the review. Moreover, the
authors demonstrated that breast CSCs express elevated
levels of EMT markers and that EMT promotes the gen-
eration of CSCs.17
In contrast to the above mentioned idea, the work done
by Tsuji et al reveals that EMT and CSCs are mutually
exclusive.18 Another recent report also indicated that
tumor initiating capacity is EMT independent in breast
cancer cell lines. The authors concluded that even though
EMT and MET had an effect on CD44 high/CD24 low levels,
cell proliferation, invasion, drug resistance and radio
resistance, it had no impact on tumor-initiating capacity
which is an important measure for the assessment of a
bonafide CSC. EMT mediated CSC formation might be
context dependent and further research is required to
confirm the role of EMT in formation of breast CSCs.
Various markers have been proposed to identify breast
CSCs. These include e in vitro markers like mammosphere
formation, surface expression of CD44 high/CD24 low and
elevated expression of aldehyde dehydrogenase (ALDH).
In vivo measurement of CSCs is based on the limiting
dilution assay whereby the tumor take is assessed by
injecting a range of cells i.e. 100k cells/site, 1k cells/site,100 cells/site and 10 cells/site. The CSC frequency is
calculated based on the tumor take. Secondary and ter-
tiary mammosphere formation in vitro and serial trans-
plantation in-vivo is used to assess the self-renewal
capacity of the CSC.
Recently, cell lineage markers are used in tumor models
to identify the hierarchy of CSCs and various studies have
demonstrated that heterogeneity exists between CSC pop-
ulations and that the cells have the capacity to interconvert
between stem and non-stem states.19
Whether different markers identify the same subpopu-
lation or different was unclear and recent work by Liu et al
suggests that ALDH is a better marker for epithelial like
breast CSCs and CD44 high/CD24 low is a better indicator of
mesenchymal like CSCs. Epithelial like CSCs proliferate
rapidly and are more localized, whereas mesenchymal like
CSCs are more invasive and are quiescent.20
The review deals primarily with breast CSCs in the
HER2þ subtype of breast cancer. However, it is important
to note that HER2 is selectively expressed in HER2-,
ERþ luminal breast CSCs and the HER2þ CSCs of HER2-
breast cancer could be targeted by employing anti-HER2
agents as listed before.21 The HER2þ CD44 High/CD24
Low breast CSCs isolated from the HER2 negative breast
cancer cells showed enhanced ALDH activity, invasiveness
and in vivo tumorigenesis, as compared to HER2-breast
CSCs.22
HER2þ CSCs display a distinct genotype as compared to
non-HER2þ CSCs through altered epigenetic regulation.
HER2 strongly regulates genes related to stem cell and
progenitor cell control.23 Moreover, HER2þ CSCs display
elevated levels of genes involved in S/G2/M transition and
reduced expression of genes involved in differentiation
and immune response.24 The following table summarizes
the features of HER2þ CSCs and non-HER2þ CSCs
(Table 3).
According to work by Magnifico et al, HER2þ CSCs are
enriched with higher HER2 mRNA levels and HER2 surface
expression as compared to the HER2þ bulk cells.25 Con-
trary to this, recent work by Diessner et al demonstrated
that CD44 high/CD24 low HER2þ breast CSCs have lower
surface expression of HER2, and possess higher endocytic
activity which renders them susceptible to targeting by T-
DM1. Moreover, the higher clinical efficacy of T-DM1 as
compared to trastuzumab could be attributed to its
ability to preferentially and efficiently target CSCs,
rather than the bulk cells.26 Sorting of HER2 high and
HER2 low populations from the mammospheres of Luminal
A subtype MCF7 cells showed an increase in stem cell
properties and markers such as OCT4, NANOG and SOX2 in
HER2 low population as compared to HER2 high popula-
tion. OCT4, SOX2 and NANOG are known to induce plu-
ripotency and thereby affect the stem cell potential.
Also, xenografts of HER2 low sorted cells from MCF7
mammospheres showed enhanced levels of CSC markers
and CSC properties, as compared to xenografts of HER2
high fraction.27
Developmentally conserved signaling pathways such as
Notch, Wnt, and Sonic Hedgehog are deemed to be critical
for the formation of CSCs. Besides these, various other
signaling pathways and signaling crosstalk could contribute
to formation of breast CSCs (Fig. 1).
Table 3 HER2þ CSCs verus Non-HER2þ CSCs.
Parameter HER2þ CSC Non-HER2þ CSC
HER2
overexpression
Observed Not observed
Subtypes Lumial A, Luminal B and HER2þ All subtypes
Anti-HER2
agents
Effective for treatment Not effective for treatment
Phenotype High ALDH activity,
mammosphere formation,
invasiveness and
tumorigenesis, as compared
to Non-HER2þ CSC.
Higher self-renewal and
replicative potential.
Low ALDH activity,
mammosphere formation,
invasiveness
and tumorigenesis,
as compared to HER2þ CSC.
Lower self-renewal and replicative
potential, as compared to HER2þ CSC.
Genotype Increased regulation of
genes related to stem
cells and progenitor
cell control. Increased
expression of genes
related to S/G2/M
transition. Reduced
expression of genes
involved in differentiation
and immune response.
Decreased regulation of genes related to
stem cells and progenitor cell control,
decreased expression of genes related to
S/G2/M transition. Increased expression
of genes involved in differentiation and
immune response, as compared to
HER2þ CSC.
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Notch signaling
Canonical Notch signaling functions in a paracrine fashion
with the ligand being expressed on the signal sending cell and
the receptor being expressed on the signal receiving cell. InFig. 1 Signaling Pathways that have been implicated in the form
cells that originated from HER2þ breast cancer have both the cap
tumor cells. Numerous pathways have been shown to promote self
pathways are developmentally conserved and promote both norma
NF-kB, IL-8-CXCR, JAK-STAT, TGF-b, and PI3K-AKT have also been
cancer stem cells.humans, there are four known Notch receptors (Notch 1e4)
and five known Notch ligands (Jagged1, Jagged2, DLL1, DLL3
and DLL4). Upon interaction with the receptor, the ligand
gets ubiquitinylated by an E3 ubiquitin ligase (Neuralized or
Mindbomb). This ubiquitinylation generates the pulling force
that enables the subsequent S2 (mediated by ADAM17/TACE
e A Disintegrin And Metalloproteinase 17/Tumor necrosis
factor Alpha Converting Enzyme) and S3 (mediated by g-
Secretase) cleavages of the receptor. The S3 cleavageation of HER2D breast cancer stem cells. Breast cancer stem
acity to self-renew and differentiate into progenitors and bulk
-renewal and differentiation. Notch, Wnt, and Sonic Hedgehog
l and cancer stem functions. Other signaling pathways such as
implicated in promoting self-renewal and differentiation of
HER2þ breast cancer stem cells 119generates Notch Intracellular Domain (NICD) which trans-
locates to the nucleus, binds directly to CSL, a transcrip-
tional repressor. Once bound, NICD recruits the coactivator,
mastermind like 1 (MAML1) as well as other coactivators
while simultaneously releasing corepressors to initiate the
transcription of Notch target genes.28
Crosstalk between HER2 and Notch signaling was
demonstrated by Osipo et al whereby they found that HER2
inhibition results in Notch1 activation and that Notch acti-
vation leads to trastuzumab resistance. Dual inhibition of
HER2 and Notch signaling using trastuzumab and Notch1
siRNA or g-Secretase Inhibitor (GSI) could prevent or
reverse trastuzumab resistance in vitro.29 In-vivo studies
reveal that combined blockade of HER2 and Notch signaling
is required in order to prevent tumor recurrence and to
reverse drug resistance.30 Recent work by Abravanel et al
indicates that Notch signaling remains activated in a subset
of dormant tumor cells after HER2 inhibition and promotes
tumor recurrence. The study was based on the bioinfor-
matics analyses of breast cancer patients and mouse model
of recurrent mammary tumorigenesis.10 In contrast to these
studies, Magnifico et al showed that HER2 levels are
controlled by Notch signaling and that Notch inhibition
through GSI or Notch1 siRNA as well as HER2 inhibition using
trastuzumab was able to reduce the levels of CSCs.25
Notch1 and Notch4 receptors are known to play important
roles in the formation of breast CSCs. Findings indicate that
the Notch4 receptor is involved in the transition of breast
cancer stem cell to progenitor cell and that Notch1 is
critical for progenitor proliferation and luminal differenti-
ation. Moreover, based on this finding, targeting Notch4
would be more effective than Notch1 to prevent tumor
recurrence.31Wnt signaling
Canonical Wnt signaling comprises the binding of Wnt ligand
with Frizzled receptor and other coreceptors like lipopro-
tein receptor-related protein (LRP)-5/6, Ryk, or Ror2.
Nineteen Wnt ligands and 10 Frizzled receptors have been
identified in humans. The interaction results in destabili-
zation of the destruction complex which consists of
Glycogen synthase kinase 3 beta (GSK3b), axin, protein
phosphatase 2A (PP2A), casein kinase 1a (CK1a) and
adenomatous polyposis coli (APC). The process requires the
Dishevelled phosphoprotein. Due to the destabilization of
the destruction complex, b-catenin is stabilized, which
then translocates to the nucleus and acts as a transcrip-
tional coactivator to mediate T-cell factor (TCF)/lympho-
cyte enhancer factor (LEF)-dependent transcription. In the
absence of Wnt ligand, the destruction complex phosphor-
ylates b-catenin which results in ubiquitinylation-mediated
proteasomal degradation of b-catenin.32
HER2 interacts with the Wnt signaling pathway through
its downstream mediators AKT and Extracellular signal-
regulated kinases (ERK). AKT and ERK kinases are known to
phosphorylate and inhibit GSK3b that leads to translocation
of b-catenin to the nucleus and transcription of Wnt-target
genes through TCF/LEF family of transcription factors.33
Trastuzumab resistant cell lines showed an upregulation of
Wnt signaling pathway ligand Wnt3. Increased Wnt3 levelsresulted in activation of Wnt/b-catenin signaling pathway.
Moreover, Wnt3 inhibition restored trastuzumab sensitivity
and reduced invasiveness.34 Tumor spheres cultured in-vitro
from the tumors derived from ErbB2 positive transgenic
mice showed an upregulation of Wnt/b-catenin target genes
as compared to mouse mammospheres and mammospheres
induced to differentiate in-vitro. This suggests that Wnt
signaling is enriched in HER2 breast CSCs relative to mam-
mary epithelial stem/progenitor cells or differentiated
mammary epithelial cells. While pharmacological inhibition
of Wnt signaling using PKF118-310 inhibited the sphere for-
mation and colony formation by primary tumor cells and
primary mammary epithelial cells, as well as by tumor-
sphere- and mammosphere-derived cells, it affected the
self-renewal of only primary tumor derived and
tumorsphere-derived cells. Primary tumor cells treated with
PKF118-310 or cells derived from PKF118-310 treated mice
failed to generate tumors in mice after transplantation
suggesting the importance of inhibiting Wnt signaling for
eradicating HER2 breast CSCs in-vitro and in-vivo.35
Hedgehog signaling
Canonical Hedgehog signaling depends on the interaction of
the Hedgehog ligand released from the secretory cell with
the Patched (Ptch) receptor expressed on a different cell.
The interaction relieves the Smoothened (Smo) complex
that is inhibited by Ptch in the absence of the ligand. The
signal transduction results in the liberation of the activated
Gli-1 protein which translocates to the nucleus and initiates
the transcription of Hedgehog target genes. Gli-1 and Ptch-
1 mediate negative feedback loop.36
Hedgehog signaling has been primarily studied in hor-
mone receptor positive and triple negative subtypes of
breast cancer. There is very little published information
describing crosstalk between HER2 and the Sonic Hedgehog
pathway.37 However, HER2 activates the Hedgehog
pathway via PI3K-Akt signaling in human esophageal
adenocarcinoma.38 Recent efforts to understand the
Hedgehog related protein expression in breast cancer
focused on tissue microarray data from 334 human cases
and revealed that Sonic hedgehog (Shh) expression was
higher in the HER2 subtype and Gli-1 expression was higher
in the luminal B HER2 positive subtype. Furthermore, the
Smo expression was higher in HER2 and triple negative
subtypes. The Gli-2 expression was higher in all the sub-
types except triple negative and predicted poor overall
survival.39
Other signaling pathways
Other than stemness related developmentally conserved
signaling pathways, various other signaling pathways are
involved in crosstalk with HER2 and are implicated in for-
mation of HER2 breast CSCs.
NF-kB signaling pathway
NF-kB (nuclear factor kappa-light-chain-enhancer of acti-
vated B cells) consists of five transcription factorse NF-kB1/
120 D. Shah, C. Osipop105, NF-kB2/p100, RelA/p65, RelB, and c-Rel, which can
homodimerize or heterodimerize. NF-kB is activated by
numerous stimuli. These include growth factors, cytokines,
viral and bacterial products, reactive oxygen species (ROS),
ultraviolet and ionizing radiation, DNAdamage and oncogenic
stress. The stimuli activate inhibitor of IkB kinase (IKK)
complex. IKK1/IKKa, IKK2/IKKb, and NEMO/IKKg are the
principal components of the complex. In the absence of
stimuli, NF-kB forms a complex with IkB and is sequestered in
the cytosol. Upon stimulation, activated IKK phosphorylates
IkB which results in ubiquitinylation and proteasomal degra-
dation of IkB. This releases NF-kB dimers from the complex
and the dimers then translocate from cytoplasm into the
nucleus and initiate the transcription of target genes.40
HER2 activates NF-kB signaling pathway in a canonical
fashion. However, IKKa plays a major role rather than IKKb
and is involved in the phosphorylation of p65 subunit at
serine 536. IKKa is primarily associated with invasive
phenotype in HER2þ breast cancer.41 IKKa is also important
for self-renewal as the cells derived from tumors of IKKa
defective knock-in mice, failed to generate secondary
mammospheres. However, no difference in NF-kB activity
was observed between the wild type and IKKa defective
knock-in mice.42
NF-kB inhibition resulted in decrease in CD44 þ cells in
HER2 dependent tumors and reduced mammosphere for-
mation in cell lines derived from HER2 dependent tumors.
The inhibition of CSCs could be possibly due to reduced
expression of Nanog and Sox2 which are critical embryonic
stem cell regulators. In this study, the phenotype was
attributed to IKKb dependent NF-kB activation.
Lentiviral shRNA kinome screen performed on non-
adherent HER2/Neu mouse tumorsphere revealed non-
canonical IkB kinase TBK1 as a vital target. Inhibition of
TBK1 lead to cellular senescence and growth inhibition of
HER2þ breast cancer cells. Senescence was attributed to
inhibition of active p65-NfkB and induction of the cell cycle
inhibitor p16(ink4a).43
These studies reveal the distinct role for IKKa and IKKb
and the possibility of differential regulation of NF-kB
pathway through canonical/non-canonical signaling.
As mentioned before, PTEN loss is commonly observed in
patients that are resistant to trastuzumab treatment. Kor-
kaya and colleagues have shown in a preclinical model, that
PTEN knockdown in HER2þ breast cancer cells results in
trastuzumab-resistant breast CSCs through inflammatory
loop mediated by IL-6 and NF-kB.44IL-8 and CXCR signaling pathway
IL-8 binds and activates CXCR-1/2 which belongs to the
seven transmembrane domain class A, rhodopsin-like gua-
nine-protein-coupled receptors (GPCRs). IL-8 and gran-
ulocyte chemotactic protein-2 (GCP-2) activate CXCR1.
CXCR2 is known to be activated by IL-8 and various other
ligands. Like other GPCRs, CXCR-1/2 associate with heter-
otrimeric G proteins, a, b and g subunits. Upon ligand
binding, guanosine diphosphate is converted to guanosine
triphosphate which results in the separation of Ga subunit
from Gbg subunit. The Ga subunit and the Gbg subunit can
activate numerous other signaling pathways. The majorones include e PI3K/Akt signaling pathway, phospholipase
C/protein kinase C (PLC/PKC) pathway and MAP Kinase
signaling pathway. Other signaling pathways include Rho,
Rac, Focal adhesion kinase and Janus Kinase/Signal Trans-
ducers and Activators of Transcription (JAK/STAT)
pathway.45
HER2 overexpression is associated with an increase in
levels of IL-8 and other CXCR 1/2 agonists. IL-8 acts through
CXCR 1/2 and leads to downstream activation of SRC ki-
nases which then transactivate HER2 and leads to mam-
mosphere formation. Combination of HER2 inhibition and
CXCR 1/2 inhibition was found to be more effective in
targeting HER2 breast CSCs.46
JAK-STAT signaling pathway
Janus kinase- JAK1, JAK2, JAK3 and TYK2 are the members
of JAK family of kinases. Upon binding of a cytokine to a
cytokine receptor, JAK kinases are recruited and activated.
The activation of JAK kinases leads to recruitment of the
STAT3/STAT5 transcription complex on specific phospho-
tyrosines of the cytokine receptor. The transcription com-
plex is then phosphorylated by JAK kinases which results in
dissociation of STATs from the cytokine receptor and for-
mation of stable homodimers and heterodimers that
translocate to the nucleus. Upon translocation into the
nucleus, the STATs bind to specific DNA sequences at the
promoter region of the genes involved in apoptosis, cell
proliferation and differentiation.47
HER2 overexpression leads to phosphorylation of STAT-3
resulting in enhancement of stem cell markers (Oct-4, Sox-
2 and CD44), tumorsphere formation and trastuzumab
resistance. STAT3 inhibition abolished the CSC phenotype
and resulted in reduced tumorsphere formation and a
decrease in stem cell markers. Combined inhibition of HER2
and STAT3 showed synergistic effect on suppression of cell
growth in-vitro.48
TGF-b signaling pathway
There are three known isoforms of Transforming growth
factor e b (TGF-b) e TGF-b1, -b2 and b3. Other ligands of
TGF-b superfamily include activins, bone morphogenetic
proteins, inhibins, and nodals. The canonical signaling
pathway is initiated when the TGF-b superfamily ligand
binds to TGF-b type II receptor (TbRII) and initiates
dimerization with the TGF-b type I receptor (TbRI) and
activation of the TbRI kinase. Receptor associated Smad
proteins (R-Smads) e Smad2 and Smad3 are phosphorylated
by the activated TbRI. The phosphorylated Smad binds
Smad4 which enables them to translocate to the nucleus
and initiate the transcription of TGF-b target genes. TbRI
and TbRII belong to transmembrane serine/threonine ki-
nases. Seven isoforms of TbRI and five isoforms of TbRII are
identified in humans and different combinations of TbRI and
TbRII have been identified for different ligands. TGF-b is
also known to signal in a Smad independent manner.49
TGF-b is known to be important for embryonic devel-
opment. However, during mammary gland development, it
acts as a growth inhibitor initially and is later on known to
promote EMT, drug resistance and metastasis. TGF-b acts as
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HER2 interacts with TGF-b at various levels. This involves i.
Transcriptional regulation of Smad target genes and path-
ways, ii Smad independent activation of PI3K/Akt pathway
and iii alteration of tumor microenvironment through
secretion of HER ligands, TGF-b and angiogenic media-
tors.51 CSCs isolated from MMTV-Her2/neu tumors show
enrichment of TGF-b responsive gene signature and
enhanced TGF-b signaling. Integrin-b3 signaling is impera-
tive for TGF-b signaling and integrin-b3-TGFb axis is
important for self-renewal and maintenance of CSCs. TGF-b
receptor inhibition led to reduction of CSCs without
affecting the overall cell survival.52
PI3-kinase-Akt signaling pathway
The phosphoinositide-3-kinase (PI3-kinase) is a heterodimer
comprised of a regulatory subunit (p85) and a catalytic
subunit (p110). The pathway is activated when the p85
subunit binds to phosphorylated tyrosine residues of re-
ceptor tyrosine kinases, i.e. insulin-like growth factor 1
receptor (IGF1R), epidermal growth factor receptor (EGFR),
or HER2. PI3-kinase mediates the conversion of membrane
bound phosphatidylinositol-4,5-bisphosphate (PIP2) to
phosphatidylinositol-3,4,5-trisphosphate (PIP3). AKT and
phosphoinositide-dependent-kinase-1 (PDK1) contain
pleckstrin homology domains that bind to PIP2 and PIP3.
This results in the translocation of AKT and PDK1 to the
plasma membrane. PDK1 partially activates AKT by phos-
phorylating threonine308. Complete activation of AKT is
achieved by phosphorylation of serine473, mediated by
mammalian target of rapamycin (mTOR) containing TORC2
complex. AKT then phosphorylates various substrates
leading to multiple effects on protein synthesis, apoptosis,
cell proliferation and metabolism. AKT is known to activate
mTOR which exists in two different complexes e mTORC1
and mTORC2. AKT activates with mTORC1 by phosphory-
lating Tsc2 and relieving the inhibition of mTORC1which
then plays a crucial role in downstream signaling, affecting
protein synthesis and cellular metabolism. Phosphatase and
tensin homolog (PTEN) is the phosphatase that mediates
the conversion of PIP3 to PIP2 and attenuates the PI3-
kinase-Akt signaling. It is known to act as a tumor sup-
pressor and its loss or mutation is implicated in breast
cancer.53
HER2 signaling leads to downstream activation of PI3K-
Akt signaling pathway as discussed before. Reports cite the
role of HER2-PI3K-FoxO-Survivin loop that is activated in
trastuzumab resistant cells and that pharmacologic inhibi-
tion of PI3K along with trastuzumab is effective in targeting
the CSCs in the fraction trastuzumab resistant cells in-vitro
and in-vivo.54 Another study reveals that when activating
mutant PIK3CA is present in HER2þ tumor, it results in anti-
HER2 therapy drug resistance, EMT and increased levels of
CSCs. PI3K inhibitor was successfully shown to reverse the
drug resistance and CSC formation.55
CSCs and tumor microenvironment
The tumor microenvironment is the environment within
which the tumor exists and its constituents are cancerassociated fibroblasts, leukocytes, mesenchymal stem
cells, lymphatic and blood endothelial cells, extracellular
matrix and the signaling molecules. The tumor microenvi-
ronment is believed to provide a niche to CSCs which helps
them to thrive and maintain an immature phenotype. The
microenvironment helps the CSCs to evade the immune
system and to undergo EMT and thus metastasize. The
microenvironment is responsible for the genetic changes
and epigenetic variation. CSCs activate or secrete various
factors in order to maintain their survival. The tumor
microenvironment also plays a pivotal role in the regulation
of bidirectional CSC and non-CSC switch.56 This could be
possibly attributed to EMT/MET plasticity that is exhibited
by the tumor cells, in order to establish themselves in the
changing microenvironment at the primary and metastatic
sites.57
Tumor niche consists of a combination of cells that carry
wild type HER2 and the ones that harbor activating HER2
mutations in the tyrosine kinase domain. Recent work by
Wang et al demonstrates that the mutations impact the
tumor microenvironment and mediates the upregulation of
growth factors like Vascular Endothelial Growth Factor
(VEGF), TGF-b and EGFR ligands like amphiregulin and TGF-
a. The secreted growth factors promote autocrine and
paracrine signaling which favors tumor growth.58
Cancer associated fibroblasts are known to mediate
trastuzumab resistance in HER2þ breast cancer through
secretion of IL-6, expansion of CSCs and by activation of
multiple signaling pathways like NF-kB, JAK/STAT3 and
PI3K/AKT.59
HER2 is selectively expressed in the CSCs of HER2-
subtype of breast cancer and this involvement of HER2 is
regulated by the tumor microenvironment. HER2 expression
is induced by Receptor activator of nuclear factor kappa-B
(RANK) ligand produced by bone osteoblasts. Moreover,
higher levels of HER2 are reported under bone metastatic
setting as compared to primary tumor and the circulating
tumor cells of HER2-breast cancer are known to express
HER2. Currently, clinical trials are under way to evaluate
the efficacy of using RANK ligand inhibitor denosumab along
with adjuvant therapy for the prevention of recurrence in
the bone or any other part in women with early stage breast
cancer and who are prone for recurrence.60Future directions and unmet needs of basic
and clinical sciences
This review describes list of signaling pathways and their
important crosstalk with HER2. However, it is important to
note that each of the above mentioned signaling pathways
can crosstalk with each other and that there might be
multiple nodes that impinge on other signaling pathways
leading to a complex web of cancer signaling crosstalk.
It is critical to identify the roles of each distinct signaling
pathways e i.e. to identify the pathway/(s) that are
important in formation of CSCs, survival of CSCs and pro-
liferation of CSCs in HER2þ breast cancer. Furthermore, it
would be vital to identify and target the central node that
necessary for the activation of multiple signaling pathways
that are important for survival and proliferation of breast
CSCs in HER2þ breast cancer. Also, targeting certain
122 D. Shah, C. Osiposignaling pathways might result in activation of compen-
satory pathways posing an important challenge for
designing drug molecules in order to target CSCs in HER2þ
breast cancer. Furthermore, there exists a plasticity be-
tween the CSCs and the non-CSCs. To eradicate the tumor
completely, it would be necessary to develop a combina-
torial approach to target the non-CSCs along with CSCs, as
non-CSCs are capable of transitioning to CSC state and vice-
versa.
Another important aspect involves identification and
targeting of dormant tumor cells. Dormancy can result from
cells completely withdrawing from the cell cycle, or by
cells proliferating at a slower rate. Dormancy is the
persistent state of disease without any signs or symptoms,
until tumor relapse is observed. Dormant tumor cells are
known to possess characteristics of CSCs. Possible ap-
proaches to target dormant tumor cells include targeting
angiogenesis, microenvironment, signaling pathways and
activating the immune system. An important challenge
exists in terms of identifying, isolating and characterizing
dormant tumor cells, as no marker exists for dormant tumor
cells and they exist in a lower frequency. Better under-
standing of the dormant cells can help in the development
of appropriate therapies to prevent the transition from
dormancy to metastasis, or tumor relapse.61
Despite our extensive efforts to identify and target CSCs
in HER2þ breast cancer, no strategy has yet been devel-
oped to isolate and target the HER2þ breast CSCs in a
clinical setting. We have not yet found an Achilles heel and
several questions remain unanswered e Will it be possible
to attain rational targeting of few signaling pathways to kill
CSCs in HER2þ breast cancer? Did evolution create plastic
CSCs in order to survive various assaults?
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